ARYA Sciences Acquisition Corp. IV announced the pricing of its $130 million IPO this evening and its shares are expected to begin trading on the NYSE under the symbol “ARYD,” Friday, February 26.
The new company aims to combine with a life sciences or medical technology target with unique therapeutics or drug candidates. ARYA IV is led by CEO Adam Stone, CFO Michael Altman, Chief Business Officer Konstantin Poukalov, and Chairman Joseph Edelman.
Total SPAC deal count for 2021 year-to-date is now 182. This offering is expected to close on Tuesday, March 2.
Goldman Sachs & Co. LLC and Jefferies LLC are serving as joint book-running managers for the offering. Kirkland & Ellis LLP is serving as Issuer’s Counsel with Skadden, Arps, Slate, Meagher & Flom LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.
Source: https://spacinsider.com/2021/02/25/arya-sciences-acquisition-corp-iv-prices-130m-ipo-2/
